Alabama Oncology considers clinical research to be an important part of our overall mission. We’re proud to provide access to cutting edge treatment options in your community, close to home.
If you think you might be interested in taking part in a clinical trial and would like to speak to someone for more information, please ask your physician or contact a clinical research coordinator at (205) 803-4389.
Alabama Oncology participates in a broad list of innovative studies that strive to advance medical science. Please see the current list of studies we have available for our patients below:
Treatment Studies:
Lung
Small Cell Lung Cancer
- Henlius ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
Breast
Triple Negative Breast Cancer
- Gilead Ascent-05: Phase III Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)
ER Positive, HER2 Negative:
- AZ Cambria-1: A phase III open label randomizsed study to assess the efficacy and safety of switching to AZD9833 vs continuing standard endocrine therapy (aromatase inhibitor or tamoxifen) in Patients with HR+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy wihtout disease recurrence.
- Genetech ML43171: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician’s Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Observational / Biomarker Studies:
Various Tumor types
Freenome Valliana: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
https://clinicaltrials.gov/study/NCT05254834
Exact Sciences ES2021-05: Multi cancer early detection (MCED) test development for newly diagnosed or recurrent cancers
https://www.exactsciences.com/Pipeline-and-Data/clinical-studies
Exact Science Ascend2: Multi cancer early detection (MCED) test development for treatment naïve solid tumors.
https://www.exactsciences.com/newsroom/press-releases/exact-sciences-to-present-late-breaking-data-from-ascend-2-study
MT7640: A biomarker study for Non-Small Cell Lung Cancer, Ovarian Cancer, and Pancreatic Cancer
https://mtgroupbio.com/
Breast
MT3805: A biomarker study for Triple Negative Breast Cancer
https://mtgroupbio.com/
Prostate
MT0282: Biomarker study for metastatic castration resistant prostate cancer (mCRPC) for patients starting a new qualifying line of treatment
https://mtgroupbio.com/
Esophageal
BMS (Bristol Myers Squibb) 6kx: A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer (PROSPECT-ESO)
https://clinicaltrials.gov/study/NCT05780736
Lymphoma
Morphosys (INCYTE) RealMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination with Lenalidomide in Patients with Relapsed or Refractory DLBCL (Diffuse Large B cell Lymphoma) (realMIND)
https://clinicaltrials.gov/study/NCT04981795
Multiple Myeloma
Janssen 54767414NAP4002: A Pilot Prospective Observational Study to Evaluate an Electronic Health Record-Based Data Collection Infrastructure for Capturing Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
https://classic.clinicaltrials.gov/ct2/show/NCT02497378